XML 29 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Mar. 08, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Trading Symbol AMLX    
Entity Registrant Name Amylyx Pharmaceuticals, Inc.    
Entity Central Index Key 0001658551    
Current Fiscal Year End Date --12-31    
Entity File Number 001-41199    
Entity Tax Identification Number 46-4600503    
Entity Address, Address Line One 43 Thorndike St.    
Entity Address, City or Town Cambridge    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02141    
City Area Code 617    
Local Phone Number 682-0917    
Entity Current Reporting Status Yes    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   66,716,388  
Entity Public Float     $ 788.1
Entity Interactive Data Current Yes    
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Security Exchange Name NASDAQ    
Entity Incorporation, State or Country Code DE    
Document Annual Report true    
Document Transition Report false    
ICFR Auditor Attestation Flag false    
Auditor Name Deloitte & Touche, LLC    
Auditor Location Boston, Massachusetts    
Auditor Firm ID 34    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2023 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2022. Portions of such definitive proxy statement for the 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.